Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368537 · ClinicalTrials.gov registry record · Phase 4
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
A Phase 4 study of Skin Diseases, Bacterial, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 550
- Enrollment target
- 20
- Study locations
NCT00368537 is a Phase 4 study of Skin Diseases, Bacterial that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 550 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT00368537, a Phase 4 study of Skin Diseases, Bacterial, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 550 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
Conditions Studied
Interventions
- DRUG Tigecycline
- DRUG ampicillin-sulbactam
Study Locations (20)
California
- - Chula Vista
- - Mission Viejo
- - National City
Illinois
- - Decatur
- - Naperville
- - Springfield
District of Columbia
- - Washington D.C.
- - Washington D.C.
Florida
- - Orlando
- - Vero Beach
Massachusetts
- - Cambridge
- - Worcester
Arizona
- - Scottsdale
Arkansas
- - Jonesboro
Colorado
- - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368537
The ClinicalTrials.gov registry entry for NCT00368537 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Diseases, Bacterial appearing as the primary indexed condition, and to 2 interventions - of which Tigecycline is the first listed.
NCT00368537 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00368537 about?
NCT00368537 is a clinical study titled "Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections". The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
What is the current status of trial NCT00368537?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 550 participants. The study started on 2006-09. Estimated completion is 2008-09.
What conditions does trial NCT00368537 study?
This clinical trial studies the following conditions: Skin Diseases, Bacterial.
What interventions are being tested in trial NCT00368537?
The interventions under investigation include: Tigecycline (DRUG), ampicillin-sulbactam (DRUG).
Who is sponsoring clinical trial NCT00368537?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00368537 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.